^
Association details:
| Biomarker: | MYCN amplification + ALK R1275Q |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma
Excerpt:
...PF-06463922 (5 mg/kg BID) resulted in rapid (within 2–3 weeks) and sustained complete tumor regression for the duration of treatment in all xenografts…Table 1…
DOI:
10.1158/2159-8290.CD-15-1056
